Abstract:Objective To investigate the effects of fluorofenidone(AKF-PD)on diabetic kidney disease in db/db mice and its possible mechanisms.Methods(1)Fifty-six mice aged 8 weeks(half male and half female),including 42 db/db mice and 14 wild-type mice were studied.Fortytwo db/db mice randomly were divided into model group(mock-treated diabetic db/db mice),AKF-PD(250 mg· kg-1· d-1)treatment group and losartan(20 mg· kg-1· d-1)treatment group.Wild-type mice and model mice were treated with vehicle(0.5％sodium carboxymethylcellulose),while the treatment groups received either AKF-PD or losartan.After 18 weeks,the blood glucose and urinary albumin were measured,the pathological changes of kidney were observed by PAS staining.The protein expressions of type Ⅳ collagen and fibronectin(FN)in kidney tissue were detected by immunohistochemistry.(2)Mouse glomerular mesangial cells(MES-13 cells)were divided into six groups:normal glucose group(5.5 mmol/L glucose),hypertonic group(5.5 mmol/L glucose+19.5 mmol/L mannitol),high glucose group(25.0 mmol/L glucose),AKF-PD group(25.0 mmol/L glucose+400 mg/L AKF-PD)and losartan group(25.0 mmol/L glucose+2 μmol/L losartan).After 72 h treatment,the expressions of type Ⅰ collagen,type Ⅳ collagen and transforming growth factor-β1(TGF-β1)mRNA were detected by realtime PCR,and the content of TGF-β1 protein in the culture supernatant was detected by ELISA.Results(1)Compared with the wild type mice,model mice had increased weight,blood glucose and glomerulosclerosis index(all P ＜ 0.01),accompanied with heavy albuminuria,glomerular hypertrophy,mesangial area expansion and deposition of collagen type Ⅳ and FN(all P ＜ 0.01).Compared with model mice,in AKF-PD and losartan groups 24 h urinary albumin and glomerulosclerosis index decreased(all P ＜ 0.01),glomerular hypertrophy and mesangial area expansion alleviated,and the protein expressions of collagen type Ⅳ and FN were inhibited(all P ＜ 0.01).(2)Compared with the normal glucose group,the mRNA expressions of type Ⅰ collagen and type Ⅳ collagen increased in high glucose group,meanwhile the mRNA and protein expressions of TGF-β1 increased(all P ＜ 0.01).In AKF-PD and losartan groups the expressions of type Ⅰ collagen,type Ⅳ collagen and TGF-β1 were inhibited as compared with high glucose group(all P ＜ 0.05).Conclusion Fluorofenidone may play an anti-fibrotic effect in db/db mice by reducing the expression of TGF-β1 and inhibiting collagen synthesis in glomerular mesangial cells.

Fluorofenidone attenuates renal fibrosis by inhibiting the mtROS-NLRP3 pathway in a murine model of folic acid nephropathy

Fluorofenidone Attenuates Hepatic Fibrosis By Suppressing The Proliferation And Activation Of Hepatic Stellate Cells

Fluorofenidone Attenuates Renal Interstitial Fibrosis by Enhancing Autophagy and Retaining Mitochondrial Function

Fluorofenidone attenuates renal fibrosis by inhibiting lysosomal cathepsin‑mediated NLRP3 inflammasome activation

The Antihepatic Fibrotic Effects of Fluorofenidone Via Mapk Signalling Pathways

Fluorofenidone Attenuates Inflammation by Inhibiting the NF-кB Pathway.

Fluorofenidone Inhibits Nicotinamide Adeninedinucleotide Phosphate Oxidase Via PI3K/Akt Pathway in the Pathogenesis of Renal Interstitial Fibrosis

Fluorofenidone Inhibits UUO/IRI-Induced Renal Fibrosis by Reducing Mitochondrial Damage

Fluorofenidone Attenuates Oxidative Stress and Renal Fibrosis in Obstructive Nephropathy Via Blocking NOX2 (gp91phox) Expression and Inhibiting ERK/MAPK Signaling Pathway

Fluorofenidone Protects Liver Against Inflammation and Fibrosis by Blocking the Activation of NF‐κB Pathway

Fluorofenidone Attenuates Tubulointerstitial Fibrosis by Inhibiting TGF-β1-Induced Fibroblast Activation

Fluorofenidone Inhibits Macrophage IL-1β Production by Suppressing Inflammasome Activity

Fluorofenidone Alleviates Renal Fibrosis by Inhibiting Necroptosis Through RIPK3/MLKL Pathway

Low-protein Diet Supplemented with Ketoacids Reduces the Severity of Renal Disease in 5/6 Nephrectomized Rats: a Role for KLF15

Fluorofenidone attenuates diabetic nephropathy and kidney fibrosis in db/db mice

Fluorofenidone Affects Hepatic Stellate Cell Activation in Hepatic Fibrosis by Targeting the TGF-β1/Smad and MAPK Signaling Pathways.

Fluorofenidone Attenuates Collagen I and Transforming Growth Factor‐β1 Expression Through a Nicotinamide Adenine Dinucleotide Phosphate Oxidase‐dependent Way in NRK‐52E Cells

Fluorofenidone protects against renal fibrosis by inhibiting STAT3 tyrosine phosphorylation

The Protective Mechanism of Fluorofenidone in Renal Interstitial Inflammation and Fibrosis

Fluorofenidone protects against acute liver failure in mice by regulating MKK4/JNK pathway

Fluorofenidone reduces renal fibrosis in diabetic kidney disease mice